David Sheneman
Los Angeles, CANPI 1093391971
Payments from drug & device makers
$1,663in general payments, 2019–2025
Across 55 payments — averaging $30.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$194
- Novartis$175
- Gilead$165
- Daiichi Sankyo Inc.$142
- Sanofi$132
- Incyte Corporation$117
- plus $738 from 15 others
What the payments were for
- Food & beverage$1,31579%
- Education$34821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $194 |
| Novartis | 7 | $175 |
| Gilead | 2 | $165 |
| Daiichi Sankyo Inc. | 6 | $142 |
| Sanofi | 4 | $132 |
| Incyte Corporation | 4 | $117 |
| Bristol Myers Squibb | 5 | $106 |
| Seagen Inc. | 1 | $99 |
| Merck | 3 | $73 |
| AbbVie | 3 | $70 |
| Geron Corporation | 2 | $59 |
| Karyopharm Therapeutics Inc. | 2 | $54 |
| Agios Pharmaceuticals, Inc. | 2 | $47 |
| Beone Medicines USA, Inc. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 1 | $40 |
| Exelixis Inc. | 1 | $31 |
| Stemline Therapeutics Inc. | 1 | $31 |
| Coherus Oncology, Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Immunocore Limited | 1 | $17 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.